Carbone, Antonino
Roulland, Sandrine
Gloghini, Annunziata
Younes, Anas
von Keudell, Gottfried
López-Guillermo, Armando
Fitzgibbon, Jude
Article History
Accepted: 29 October 2019
First Online: 12 December 2019
Competing interests
: A.Y. receives research support from BMS, Curis, Janssen, Merck, Roche and Syndax; honoraria from Abbvie, Curis, Epizyme, Janssen, Merck, Roche and Takeda; and has a consulting role for Biopath, Celgene, Epizyme, HCM, Roche and Xynomics. G.v.K. receives honoraria from Pharmacyclics and has a consulting or advisory role for Bayer, Genentech and Pharmacyclics. A.L.-G. receives research funding from Roche and Gilead and has an advisory role for Bayer, Gilead, Janssen, Novartis, Pfizer (not personal fees) and Roche. J.F. receives research funding from Epizyme and honoraria from Gilead and Roche. All other authors declare no competing interests.